Psychosis with use of amphetamine drugs, methylphenidate and atomoxetine in adolescent and adults
Conclusion
Our study suggests that amphetamine use is associated with a higher reporting of psychotic symptoms, compared with methylphenidate use.
Clinical implications
The prescription of psychostimulants should consider this potential adverse effect when assessing the benefit–risk balance. (Source: Evidence-Based Mental Health)
Source: Evidence-Based Mental Health - April 12, 2024 Category: Psychiatry & Psychology Authors: Hamard, J., Rousseau, V., Durrieu, G., Garcia, P., Yrondi, A., Sommet, A., Revet, A., Montastruc, F. Tags: Open access Pharmacological treatments Source Type: research
Individualized atomoxetine response and tolerability in children with ADHD receiving different dosage regimens: the need for CYP2D6 genotyping and therapeutic drug monitoring to dance together
Translational Psychiatry, Published online: 19 March 2024; doi:10.1038/s41398-024-02859-2Individualized atomoxetine response and tolerability in children with ADHD receiving different dosage regimens: the need for CYP2D6 genotyping and therapeutic drug monitoring to dance together (Source: Translational Psychiatry)
Source: Translational Psychiatry - March 19, 2024 Category: Psychiatry Authors: Hong-Li Guo Dan-Dan Wu Di Fu Yue Li Jie Wang Yuan-Yuan Zhang Wei-Jun Wang Jian Huang Wei-Rong Fang Jing Xu Ya-Hui Hu Qian-Qi Liu Feng Chen Source Type: research
Medication Treatment for ADHD Linked to Lower Two-Year Risk of Dying
People with attention-deficit/hyperactivity disorder (ADHD) who begin taking medications for the condition within three months of their diagnosis may have a lower risk of dying within two years compared with their peers who do not take ADHD medications, astudy inJAMA has found.Zheng Chang, Ph.D., of the Karolinska Institutet in Stockholm and colleagues examined data from 148,578 Swedish individuals aged 6 to 64 years who had an incident diagnosis of ADHD from 2007 through 2018 and no ADHD medication dispensation for at least 18 months prior to their diagnosis. They followed the patients from ADHD diagnosis for two years or...
Source: Psychiatr News - March 15, 2024 Category: Psychiatry Tags: ADHD attention-deficit/hyperactivity disorder JAMA Karolinska Institutet medication mortality stimulants unnatural deaths Source Type: research
Erratum: The Combination of Aroxybutynin and Atomoxetine in the Treatment of Obstructive Sleep Apnea (MARIPOSA): A Randomized Controlled Trial
Am J Respir Crit Care Med. 2024 Mar 15;209(6):767. doi: 10.1164/rccm.v209erratum3.NO ABSTRACTPMID:38488615 | DOI:10.1164/rccm.v209erratum3 (Source: Am J Respir Crit Car...)
Source: Am J Respir Crit Car... - March 15, 2024 Category: Intensive Care Source Type: research
Erratum: The Combination of Aroxybutynin and Atomoxetine in the Treatment of Obstructive Sleep Apnea (MARIPOSA): A Randomized Controlled Trial
Am J Respir Crit Care Med. 2024 Mar 15;209(6):767. doi: 10.1164/rccm.v209erratum3.NO ABSTRACTPMID:38488615 | DOI:10.1164/rccm.v209erratum3 (Source: American Journal of Respiratory and Critical Care Medicine)
Source: American Journal of Respiratory and Critical Care Medicine - March 15, 2024 Category: Respiratory Medicine Source Type: research
Erratum: The Combination of Aroxybutynin and Atomoxetine in the Treatment of Obstructive Sleep Apnea (MARIPOSA): A Randomized Controlled Trial
Am J Respir Crit Care Med. 2024 Mar 15;209(6):767. doi: 10.1164/rccm.v209erratum3.NO ABSTRACTPMID:38488615 | DOI:10.1164/rccm.v209erratum3 (Source: Respiratory Care)
Source: Respiratory Care - March 15, 2024 Category: Respiratory Medicine Source Type: research
Erratum: The Combination of Aroxybutynin and Atomoxetine in the Treatment of Obstructive Sleep Apnea (MARIPOSA): A Randomized Controlled Trial
Am J Respir Crit Care Med. 2024 Mar 15;209(6):767. doi: 10.1164/rccm.v209erratum3.NO ABSTRACTPMID:38488615 | DOI:10.1164/rccm.v209erratum3 (Source: Am J Respir Crit Car...)
Source: Am J Respir Crit Car... - March 15, 2024 Category: Intensive Care Source Type: research
Erratum: The Combination of Aroxybutynin and Atomoxetine in the Treatment of Obstructive Sleep Apnea (MARIPOSA): A Randomized Controlled Trial
Am J Respir Crit Care Med. 2024 Mar 15;209(6):767. doi: 10.1164/rccm.v209erratum3.NO ABSTRACTPMID:38488615 | DOI:10.1164/rccm.v209erratum3 (Source: American Journal of Respiratory and Critical Care Medicine)
Source: American Journal of Respiratory and Critical Care Medicine - March 15, 2024 Category: Respiratory Medicine Source Type: research
Erratum: The Combination of Aroxybutynin and Atomoxetine in the Treatment of Obstructive Sleep Apnea (MARIPOSA): A Randomized Controlled Trial
Am J Respir Crit Care Med. 2024 Mar 15;209(6):767. doi: 10.1164/rccm.v209erratum3.NO ABSTRACTPMID:38488615 | DOI:10.1164/rccm.v209erratum3 (Source: Respiratory Care)
Source: Respiratory Care - March 15, 2024 Category: Respiratory Medicine Source Type: research
Erratum: The Combination of Aroxybutynin and Atomoxetine in the Treatment of Obstructive Sleep Apnea (MARIPOSA): A Randomized Controlled Trial
Am J Respir Crit Care Med. 2024 Mar 15;209(6):767. doi: 10.1164/rccm.v209erratum3.NO ABSTRACTPMID:38488615 | DOI:10.1164/rccm.v209erratum3 (Source: Am J Respir Crit Car...)
Source: Am J Respir Crit Car... - March 15, 2024 Category: Intensive Care Source Type: research
Erratum: The Combination of Aroxybutynin and Atomoxetine in the Treatment of Obstructive Sleep Apnea (MARIPOSA): A Randomized Controlled Trial
Am J Respir Crit Care Med. 2024 Mar 15;209(6):767. doi: 10.1164/rccm.v209erratum3.NO ABSTRACTPMID:38488615 | PMC:PMC10945062 | DOI:10.1164/rccm.v209erratum3 (Source: American Journal of Respiratory and Critical Care Medicine)
Source: American Journal of Respiratory and Critical Care Medicine - March 15, 2024 Category: Respiratory Medicine Source Type: research
Erratum: The Combination of Aroxybutynin and Atomoxetine in the Treatment of Obstructive Sleep Apnea (MARIPOSA): A Randomized Controlled Trial
Am J Respir Crit Care Med. 2024 Mar 15;209(6):767. doi: 10.1164/rccm.v209erratum3.NO ABSTRACTPMID:38488615 | PMC:PMC10945062 | DOI:10.1164/rccm.v209erratum3 (Source: Am J Respir Crit Car...)
Source: Am J Respir Crit Car... - March 15, 2024 Category: Intensive Care Source Type: research
Genotoxic and genoprotective effects of some antipsychotic drugs, methylphenidate and atomoxetine on human lymphocytes and HepG2 cells
CONCLUSIONS: As a result, the genotoxicity of the drugs was found to be dose-dependent, and all drugs showed a genoprotective effect on DNA-damaged cells.PMID:38436168 | DOI:10.26355/eurrev_202402_35456 (Source: Pharmacological Reviews)
Source: Pharmacological Reviews - March 4, 2024 Category: Drugs & Pharmacology Authors: S K Sezer S Yuksel I Ucuz Source Type: research
Genotoxic and genoprotective effects of some antipsychotic drugs, methylphenidate and atomoxetine on human lymphocytes and HepG2 cells
CONCLUSIONS: As a result, the genotoxicity of the drugs was found to be dose-dependent, and all drugs showed a genoprotective effect on DNA-damaged cells.PMID:38436168 | DOI:10.26355/eurrev_202402_35456 (Source: European Review for Medical and Pharmacological Sciences)
Source: European Review for Medical and Pharmacological Sciences - March 4, 2024 Category: Drugs & Pharmacology Authors: S K Sezer S Yuksel I Ucuz Source Type: research
Genotoxic and genoprotective effects of some antipsychotic drugs, methylphenidate and atomoxetine on human lymphocytes and HepG2 cells
CONCLUSIONS: As a result, the genotoxicity of the drugs was found to be dose-dependent, and all drugs showed a genoprotective effect on DNA-damaged cells.PMID:38436168 | DOI:10.26355/eurrev_202402_35456 (Source: Pharmacological Reviews)
Source: Pharmacological Reviews - March 4, 2024 Category: Drugs & Pharmacology Authors: S K Sezer S Yuksel I Ucuz Source Type: research
